The multicenter observational non-interventional study of combination anti-tuberculosis drugs used in treatment of pulmonary tuberculosis patients

The objective of the study: to run a multicenter non-interventional observational study to assess treatment outcomes in tuberculosis patients receiving combination drugs with fixed doses, and to evaluate tolerability and safety of these drugs.

Subjects and methods. 13 TB units participated in this study which lasted from 2016 to 2018. The primary population (PP) included of 489 patients, after applying the exclusion criteria – the subpopulation (subPP) included 267 patients with newly detected pulmonary tuberculosis and relapses who received treatment as per chemotherapy regimen I or III. Descriptive statistics methods were used for statistical data processing.

Results. Of all PP, 267 (54.6%) completed the main course of chemotherapy. (subPP). Out of 489 patients, treatment was discontinued in 118 (24.1%) of them. Primary drug resistance was detected in 30 (6.1%) patients out of 489 patients, secondary drug resistance – in 74 (15.1%) of 489. In subPP, by the end of the intensive phase the sputum conversion was achieved in 78 (96.3%) of 81 patients. Clinical and X-ray changes had been observed in this subgroup for 106.2 to 63.3 days (median 90). The duration of the intensive phase in the subPP made 107.9 ± 50.5 days. In safety assessment, 191 adverse events (AE) were registered in 149 (30.5%) of 489 patients. By severity, most AEs were minor (164 out of 191), moderate AEs were less frequent (20 out of 191), and there were 7 cases of serious AEs. 61 AEs in 57 (38.2%) out of 149 patients were confidently associated with in-take of the studied drugs. The structure of those AEs, transient transaminase level elevation prevailed (45 (73.8%) of 61 AEs, but there was a single case (1.6%) drug-induced hepatitis). Among the serious AEs, two cases were safely resolved by the end of the protocol, two of them were fatal in TB/HIV co-infection, and three cases were diagnosed with cancer.

1. Аstakhova А.V., Lepakhin V.K. Lekarstva: neblagopriyantye pobochnye effekty i kontrol bezopasnosti. [Drugs: adverse reactions and safety control.] 2nd ed., Moscow, EKSMO Publ., 2008, 256 p.

2. Balasanyants G.S. Social aspects of tuberculous infection. Sotsiologiya Meditsiny, 2013, no. 2 (23), pp. 28-32. (In Russ.)

3. Berdnikov R.B., Grinberg L.M., Kondrashov D.L. Pathomorphosis of tuberculosis and algorithms for pathological anatomical diagnosis. Meditsinsky Alyans, 2013, no. 4, pp. 11-17. (In Russ.)

4. Vasilyeva I.А., Samoylova А.G., Zimina V.N., Komissarova O.G., Bagdasaryan T.R., Lovacheva O.V. Treatment of tuberculosis: past experience, current state and prospectives. Tuberculosis and Lung Diseases, 2013, vol. 90, no. 5, pp. 031-038. (In Russ.)

5. Volskaya E.A. Fundamentals of good practice for non-interventional drug research. Kachestvennaya Klinicheskaya Praktika, 2011, no. 1, pp. 19-24. (In Russ.)

6. Golubchikov P.N., Kruk E.А., Mishustin S.P., Petrenko T.I., Kudlay D.А. Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 8, pp. 38-45. (In Russ.)

7. Zinovyev I.P., Ustyuzhaninova А.S., Kokovikhina I.А. The efficacy of complex treatment of patients with infiltrative pulmonary tuberculosis and primary poly-resistance of Mycobacterium tuberculosis. Ftisiatriya i Pulmonologiya, 2011, no. 2, pp. 210-211. (In Russ.)

8. Mokhireva L.V. Effektivnost primeneniya kombinirovannykh protivotuberkuleznykh preparatov u bolnykh vpervye vyavlennym tuberkulezom legkikh: Diss. Doc. med. nauk. [The efficacy of the use of combination anti-tuberculosis drugs in patients with newly diagnosed pulmonary tuberculosis. Doc. Diss.]. 14.01.16. Moscow Medical Academy, Moscow, 2013, 258 p.

9. National Standard of the Russian Federation GOST P 52379-2005 On Good Clinical Practice.(In Russ.) (Available: http://docs.cntd.ru/document/1200041147 Accessed 17.08.17).

10. Otraslevye i ekonomicheskie pokazateli protivotuberkuleznoy raboty v 2016-2017 gg. Analiticheskiy obzor osnovnykh pokazateley i statisticheskiye materialy. [Sectorial and economic rates for TB control in 2016-2017. Analysis of main rates and statistic materials]. S.A. Sterlikov, eds., Moscow, RIO TSNIIOIZ Publ., 2018, 81 p.

11. Edict no. 50 by RF MoH as of 13.02.2004 On Introduction of Registration and Reporting Documents for Tuberculosis Monitoring. (In Russ.)

12. Edict no. 951 by RF MoH as of 29.12.2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics and Treatment. (In Russ.)

13. Sokolova G.B., Mozhokina G.N., Elistratova N.А. New Russian combination anti-tuberculosis drugs of phthizoetam and phthizopiram. Bolshoy Medetsinskiy Journal o Tuberkuleze, 2000, no. 9, pp. 26-27. (In Russ.)

14. Starshinova А.А., Kudlay D.А., Dovgalyuk I.F., Basantsova N.Yu., Zinchenko Yu.S., Yablonskiy P.K. Efficacy of new methods of immunodiagnostics of tuberculous infection in the Russian Federation. Pediatriya. Journal im. G.N. Speranskogo, 2019, vol. 98, no. 4, pp. 229-235. (In Russ.)

15. Federal Law no. 61 as of 12.04.2010 On Drugs Turnover.(In Russ.) (http://www.consultant.ru/document/cons_doc_LAW_99350/ Accessed as of 29.11.19).

16. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities. 01.05.2001.

17. Division of Microbiology and Infection Diseases (DMID) adult toxicity table. National In stitute of Allergy and Infectious Diseases, Bethesda, 2007. (http:. www. niaid.nih. gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox. pdf (Accessed as of: 09.07.2013).

18. Gallardo C.R., Rigau Comas D., Valderrama RodríguezA., RoquéiFiguls M., Parker L. A., Caylà J., Bonfill Cosp X. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2016: 5. http://www.cochranelibrary.com.

19. Lienhardt C., Cook S.V., Burgos M., Yorke-Edwards V., Rigouts L, Anyo G., Kim S.J., Jindani A., Enarson D.A., Nunn A.J. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA, 2011, vol. 305, no. 14, pp. 1415-1423.

20. Shur K.V., Umpeleva T.V., Bekker O.B., Maslov D.A., Zaychikova M.V., Vakhrusheva D.V., Danilenko V.N. Compilation of the Mycobacterium tuberculosis Beijing-b0 lineage sample and identifying predictors of immune dysfunction in source patients. Bulletin of Russian State Medical University, 2018, no. 3, pp. 23-28.

21. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J.Clin.Epidemiol., 2008, no. 61, pp. 344-349.